The problem of late allograft loss in kidney transplantation

Minerva Urologica e Nefrologica

Volumn 55, Issue 1, 2003, Pages 1-11

  Cardarelli, F ^b   Saidman, S ^b   Theruvath, T ^b   Tolkoff Rubin, N ^b   Cosimi, A B ^b   Pascual, M ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b NONE

Author keywords

Graft rejection; Immunosupressive agents; Kidney transplantation

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

GRAFT FAILURE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; HUMORAL IMMUNITY; HYPERLIPIDEMIA; KIDNEY ALLOGRAFT; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; RECIPIENT; REVIEW; T LYMPHOCYTE ACTIVATION;

CAUSE OF DEATH; CHRONIC DISEASE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; TIME FACTORS;

EID: 0038110818     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Denton MD, Magee CM, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999;353:1083-91.
2. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342:605-12.
3. Gridelli B, Remuzzi G. Strategies for making more organs available for transplantation. N Engl J Med 2000;343:404-10.
4. Suthanthiran M, Morris RE, Strom TB. Immunosuppressants: cellular and molecular mechanisms of action. Am J Kidney Dis 1996;28:159-72.
5. Ponticelli C, Villa M, Cesana B, Montagnino G, Tarantino A. Risk factors for late kidney allograft failure. Kidney Int 2002;62:1848-54.
6. Howard RJ, Patton PR, Reed AI, Hemming AW, Van der Werf WJ, Pfaff WW et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002;73:1923-8.
7. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002;346: 580-90.
8. Hume DM, Merrill JP, Miller BJ. Experience with renal homotransplantation in the human: report of nine cases. J Clin Invest 1955;34:327-83.
9. Murray JE, Merrill JP, Harrison JH. Renal homotransplantation in identical twins. Surg Forum 1955;6: 432-6.
10. Hamburger J, Vaysse J, Crosnier J. Transplantation of a kidney between nomonozygotic twins after irradiation with good function at the fourth month. Presse Med 1959;67:1771-5.
11. Murray JE, Merrill JP, Dammin GJ. Study of transplantation immunity after total body irradiation: clinical and experimental investigation. Surgery 1960;48:272-84.
12. Calne RY. The rejection of renal homografts: inhibition in dogs by 6-mercaptopurine. Lancet 1960;1: 417-8.
13. Russell PS, Winn HJ. Transplantation (first of three parts). N Engl J Med 1970;282:786-93.
14. Russell PS, Winn HJ. Transplantation (second of three parts). N Engl J Med 1970;282:848-54.
15. Russell PS, Winn HJ. Transplantation (third of three parts). N Engl J Med 1970;282:896-906.
16. Suthanthiran M, Strom TB. Renal Transplantation. N Engl J Med 1994;331:365-76.
17. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: The concept of accelerated Senescence. J Am Soc Nephrol 1999;10:167-81.
18. Paul LC. Chronic allograft nephropathy: an update. Kidney Int 1999;56:783-93.
19. Pascual M, Swinford RD, Ingelfinger JR, Williams WW, Cosimi AB, Tolkoff-Rubin N. Chronic rejection and chronic cyclosporine toxicity in renal allografts. Immunol Today 1998;19:514-9.
20. Cosimi AB, Colvin RB, Burton RC, Rubin RH, Goldstein G, Kung PC et al. Use of monoclonal antibodies to T-cell subsets for immunological monitoring and treatment in recipients of renal allografts. N Engl J Med 1981;305:308-14.
21. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Baker C. The International Mycophenolate Mofetil Renal Transplant Groups. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of 3 randomized, double blind, clinical studies in prevention of rejection. Transplantation 1997;63: 39-47.
22. Miller J, Mendez R, Pirsch JD, Jensik SC. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. Transplantation 2000;69:875-80.
23. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997;350:1193-8.
24. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338:161-5.
25. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study. The Rapamune US Study Group. Lancet 2000;15:194-202.
26. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999;341:1725-30.
27. Hunsicker LG. A survival advantage for renal transplantation. N Engl J Med 1999;342:1762-3.
28. Tilney NL. Chronic Rejection. In: Ginns LC, Cosimi AB, Morris PJ, editors. Transplantation. Malden: Blackwell Science, Inc.; 1999.p.43-59.
29. Porter KA, Owen MS, Mowbray JF, Thomson WB, Kenyon JR, Peart WS. Obliterative vascular changes in four human kidney homotransplants. Br Med J 1963;14: 639-45.
30. Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993;55: 752-7.
31. Sayegh MH. Why do we reject a graft? Role of indirect allorecognition in graft rejection. Kidney Int 1999;56: 1967-79.
32. Morris PJ. Renal Transplantation. In: Ginns LC, Cosimi AB, Morris PJ, editors. Transplantation. Malden: Blackwell Science, Inc.; 1999.p.285-311.
33. Hostetter TH. Chronic transplant rejection. Kidney Int 1994;46:266-79.
34. Colvin RB. The renal allograft biopsy. Kidney Int 1996;50:1069-82.
35. Lajoie G. Antibody-mediated rejection of human renal allografts: an electron microscopic study of peritubular capillaries. Ultrastruct Pathol 1997;21:235-42.
36. Ponticelli C. Progression of renal damage in chronic rejection. Kidney Int 2000;57(Suppl 75):S62-70.
37. Tullius SG, Hancock WW, Heemann U, Azuma H, Tilney NL. Reversibility of chronic renal allograft rejection. Critical effect of time after transplantation suggests both host immune dependent and independent phases of progressive injury. Transplantation 1994;58:93-9.
38. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998;338:1813-21.
39. Shirwan H. Chronic allograft rejection. Transplantation 1999;68:715-26.
40. Jeannet M, Pinn VW, Flax MH, Winn HJ, Russell PS. Humoral antibodies in renal allotransplantation in man. N Engl J Med 1970;282:111-7.
41. Hardy M, Suciu-Foca N, McKiernan T, Rohowsky C, Cianci J, Jacob J et al. The development and specificity of anti-B-cell antibodies during humoral rejection of kidney allografts. Transplant Proc 1979;11:389-92.
42. Martin S, Dyer PA, Mallick NP, Gokal R, Harris R, Johnson RWG. Posttransplant antidonor lymphocytotoxic antibody production in relation to graft outcome. Transplantation 1987;44:50-3.
43. Scornik JC, Salomon DR, Lim PB, Howard RJ, Pfaff WW. Posttransplant antidonor antibodies and graft rejection. Transplantation 1989;47:287-90.
44. Greger B, Busing M, Hebart H, Mellert J, Hopt UT, Lauchart W. The development of a positive donor-specific cross-match after kidney transplantation is detrimental to the graft. Transplant Proc 1989;21:750-1.
45. Halloran PH, Schlaut J, Solez K, Srinivasa NS. The significance of the anti-class I response. Transplantation 1992;53:550-5.
46. Al-Hussein KA, Shenton BK, Bell A, Talbot D, Clark KR, Rigg KM et al. Characterization of donor-directed antibody class in the posttransplant period using flow cytometry in renal transplantation. Transpl Int 1994;7:182-9.
47. Davenport A, Younie ME, Parsons J, Klouda PT. Development of cytotoxic antibodies following renal allograft transplantation is associated with reduced graft survival due to chronic vascular rejection. Nephrol Dial Transplant 1994; 9:1315-9.
48. Lobo PI, Spencer CE, Stevenson WC, Pruett TL. Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor-specific lymphocytotoxin. Transplantation 1995;59:357-60.
49. Trpkov K, Campbell P, Pazderka F, Cockfield S, Solez K, Halloran PF. Pathologic features of acute renal allograft rejection associated with donor-specific antibody. Transplantation 1996;61:1586-92.
50. Monteiro F, Buelow R, Mineiro C, Rodrigues H, Kalil J. Identification of patients at high risk of graft loss by pre- and posttransplant monitoring of anti-HLA class I IgG antibodies by Enzyme-Linked Immunosorbent Assay. Transplantation 1997;63:542-6.
51. Utzig MJ, Blumke M, Wolff-Vorbeck G, Lang H, Kirste G. Flow cytometry cross-match. Transplantation 1997;63:551-4.
52. Costa AN, Scolari MP, Iannelli S, Buscaroli A, D'Arcangelo GL, Brando B et al. The presence of posttransplant HLA-specific IgG antibodies detected by Enzyme-Linked Immunosorbent Assay correlates with specific rejection pathologies. Transplantation 1997;63: 167-9.
53. Abe M, Kawai T, Futatsuyama K, Tanabe K, Fuchinoue S, Teraoka S et al. Postoperative production of antidonor antibody and chronic rejection in renal transplantation. Transplantation 1997;63:1616-9.
54. Kerman RH, Susskind B, Kerman DH, Lam M, Gerolami K, Williams J et al. Anti-HLA antibodies detected in posttransplant renal allograft recipient sera correlate with chronic rejection. Transplant Proc 1997;29: 1515-6.
55. Schonemann C, Groth J, Leverenz S, May G. HLA class I and class II antibodies. Transplantation 1998;65: 1519-23.
56. Christiaans MHL, Overhof-De Roos R, Nieman F, van Hooff JP, van den Berg-Loonen EM. Donor-specific antibodies after transplantation by flow cytometry. Transplantation 1998;65:427-33.
57. Piazza A, Adorno D, Poggi E, Borrelli L, Buonomo O, Pisani F et al. Flow cytometry crossmatch: a sensitive technique for assessment of acute rejection in renal transplantation. Transplantat Proc 1998;30:1769-71.
58. Kimikawa M, Tojimbara T, Nakajima I, Fuchinoue S, Teraoka S, Toma H et al. Posttransplant antidonor antibodies and chronic rejection in renal transplantation. Transplant Proc 1999;31:2872-3.
59. Crespo M, Pascual M, Tolkoff-Rubin N, Mauiyyedi S, Collins AB, Fitzpatrick D et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001;71:652-8.
60. Mauiyyedi S, Della Pelle P, Saidman S, Collins AB, Pascual M, Tolkoff-Rubin N et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001;12:574-82.
61. Piazza A, Poggi E, Borrelli L, Servetti S, Monaco PI, Buonomo O et al. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: posttransplant analysis using flow cytometric techniques. Transplantation 2001;71:1106-12.
62. Supon P, Costantino D, Hao P, Cagle L, Hahn A, Conti DJ et al. Prevalence of donor-specific anti-HLA antibodies during episodes of renal allograft rejection. Transplantation 2001;71:577-80.
63. Nickerson P, Karpinski M, Rush D, Jeffrey J, Pochinco D. De novo anti-HLA antibodies post-kidney transplantation are uncommon, but may be associated with the development of chronic rejection. Transplantation 2002; 74(Suppl):273(A1077).
64. Bohmig GA, Exner M, Habicht A, Schillinger M, Lang U, Kletzmayr J et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002;13:1091-9.
65. Lee PC, Terasaki PI, Takemoto SK, Lee PH, Hung CJ, Chen YL et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002;74:1192-4.
66. Mohanakumar T, Giedlin MA, Rhodes CL, DuVall CH, Mendez-Picon G, Kaplan AM et al. Relationship of B cell alloantibodies to renal allograft survival. Transplantation 1979;27:273-8.
67. Pierce JC, Kay S, Lee HM. Donor-specific IgG antibody and the chronic rejection of human renal allografts. Surgery 1975;78:14-21.
68. Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts 2. Importance of humoral immunity. J Immunol 1994;152: 5135-41.
69. Russell PS, Chase CM, Colvin RB. Alloantibody-and T cell-mediated immunity in the pathogenesis of transplant arteriosclerosis. Transplantation 1997;64:1531-6.
70. Feucht HE, Opelz G. The humoral immune response towards HLA class II determinants in renal transplantation. Kidney Int 1996;50:1464-75.
71. Sundaresan S, Mohanakumar T, Smith MA, Trulock EP, Lynch J, Phelan DL et al. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation 1998;65: 648-53.
72. McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000;69:319-26.
73. Theruvath TP, Saidman SL, Mauiyyedi S, Delmonico FL, Williams WW, Tolkoff-Rubin N et al. Control of antidonor antibody production with Tacrolimus and Mycophenolate Mofetil in renal allograft recipients with chronic rejection. Transplantation 2001;72:77-83.
74. Collins AB, Schneeberger EE, Pascual MA, Saidman SL, Williams WW, Tolkoff-Rubin N et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999;10:2208-14.
75. Regele H, Bohmig GA, Habicht A, Gollowitzer D, Schillinger M, Rockenschaub S et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002;13:2371-80.
76. Theruvath T, Saidman S, Tolkoff-Rubin N, Williams W, Mauiyyedi S, Collins B et al. Prevalence of chronic humoral rejection in chronic renal allograft dysfunction. Am J Transpl. 2001;1(Suppl 1):360(A896).
77. Danovitch GM, Irish WD. Renal transplant recipients with DGF have long-term impairment of renal function. J Am Soc Nephrol 2000;11:685(A3603).
78. Shoskes DA, Cecka JM. Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. Transplantation 1998;66:1697-701.
79. Shoskes DA, Cacka JM. Effect of delayed graft function on short- and long-term kidney graft survival. Clin Transplant 1997;0:297-303.
80. Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996;50:1089-100.
81. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK 506 Kidney Transplant Study Group. Transplantation 1998;66:1736-40.
82. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int 1996;49: 518-24.
83. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998;53:217-22.
84. Wissing KM, Abramowicz D, Broeders N, Vereerstraeten P. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation 2000;70:464-72.
85. Alonso DR, Starek PK, Minick CR. Studies on the pathogenesis of atheroarteriosclerosis induced in rabbit cardiac allografts by the synergy of graft rejection and hypercholesterolemia. Am J Pathol 1977;87:415-42.
86. Vollmer E, Bosse A, Bogeholz J, Roessner A, Blasius S, Fahrenkamp A et al. Apolipoproteins and immunohistological differentiation of cells in the arterial wall of kidneys in transplant arteriopathy. Morphological parallels with atherosclerosis. Pathol Res Pract 1991;187:957-62.
87. Weir MR, Anderson L, Fink JC, Gabregiorgish K, Schweitzer EJ, Hoehn-Saric E et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997;64:1706-10.
88. Pascual M, Williams WW, Cosimi AB, Delmonico FL, Farrell ML, Tolkoff-Rubin N. Chronic renal allograft dysfunction: a role for mycophenolate mofetil? Transplantation 2000;69:1749-50.
89. Islam MS, Francos GC, Dunn SR, Burke JF Jr. Mycophenolate mofetil and reduction in cyclosporine dosage for chronic renal allograft dysfunction. Transplant Proc 1998;30:2230-1.
90. Ferraris JR, Tambutti ML, Redal MA, Bustos D, Ramirez JA, Prigoshin N. Conversion from azathioprine to mycophenolate mofetil in pediatric renal transplant recipients with chronic rejection. Transplantation 2000;70: 297-301.
91. Hueso M, Bover J, Seron D, Gil-Vernet S, Sabate I, Fulladosa X et al. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation 1998;66:1727-31.
92. Manu MA, Tanabe K, Ishikawa N, Tokumoto T, Oshima T, Shinmura H et al. Tacrolimus rescue for resistant rejection, chronic rejection, and immunoglobulin a nephropathy of renal allografts under primary cyclosporine immunosuppression. Transplant Proc 1999;31: 2853-5.
93. Matas AJ, Gillingham KJ, Sutherland DER. Half-life and risk factors for kidney transplant outcome: Importance of death with function. Transplantation 1993;55:757-61.
94. West M, Sutherland DER, Matas AJ. Kidney transplant recipients who die with functioning grafts: Serum creatinine level and cause of death. Transplantation 1996;62:1029-30.
95. Valente JF, Hariharan S, Peddi VR, Schroeder TJ, Ogle CK, Alexander JW et al. Causes of renal allograft loss in black vs white transplant recipients in the cyclosporine era. Clin Transplant 1997;11:231-6.
96. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000;57: 307-13.
97. Arrazola L, Prieto M, Moss A, Humar A, Matas A. Death with function (DWF)-The next major hurdle. Transplantation 1999;67:S238.
98. Prommool S, Jhangri GS, Cockfield SM, Halloran PE Time dependency of factors affecting renal allograft survival. J Am Soc Nephrol 2000;11:565-73.
99. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000;11:1735-43.